21,014 Shares in Bioventus Inc. (NYSE:BVS) Purchased by Olympiad Research LP

Olympiad Research LP acquired a new position in shares of Bioventus Inc. (NYSE:BVS) in the third quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 21,014 shares of the company’s stock, valued at approximately $251,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Renaissance Technologies LLC increased its position in shares of Bioventus by 401.5% during the 2nd quarter. Renaissance Technologies LLC now owns 503,175 shares of the company’s stock worth $2,893,000 after purchasing an additional 402,841 shares during the last quarter. Marshall Wace LLP grew its position in Bioventus by 38.2% in the 2nd quarter. Marshall Wace LLP now owns 332,291 shares of the company’s stock valued at $1,911,000 after acquiring an additional 91,843 shares in the last quarter. LSV Asset Management acquired a new position in Bioventus in the 1st quarter valued at about $1,170,000. American Century Companies Inc. grew its position in Bioventus by 289.5% in the 2nd quarter. American Century Companies Inc. now owns 169,161 shares of the company’s stock valued at $973,000 after acquiring an additional 125,736 shares in the last quarter. Finally, Panagora Asset Management Inc. acquired a new position in Bioventus in the 2nd quarter valued at about $787,000. 62.94% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Bioventus

In related news, Director John A. Bartholdson bought 25,500 shares of the company’s stock in a transaction dated Monday, August 19th. The shares were acquired at an average price of $8.55 per share, with a total value of $218,025.00. Following the completion of the acquisition, the director now owns 6,939,357 shares in the company, valued at approximately $59,331,502.35. This trade represents a 0.00 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, Director John A. Bartholdson bought 80,000 shares of the company’s stock in a transaction dated Friday, August 16th. The shares were acquired at an average price of $8.55 per share, with a total value of $684,000.00. Following the completion of the acquisition, the director now owns 6,913,857 shares in the company, valued at approximately $59,113,477.35. This trade represents a 0.00 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director John A. Bartholdson acquired 25,500 shares of the company’s stock in a transaction that occurred on Monday, August 19th. The shares were acquired at an average cost of $8.55 per share, for a total transaction of $218,025.00. Following the acquisition, the director now directly owns 6,939,357 shares of the company’s stock, valued at $59,331,502.35. This trade represents a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 32.90% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several research firms have weighed in on BVS. Canaccord Genuity Group lifted their target price on Bioventus from $12.00 to $15.00 and gave the company a “buy” rating in a research report on Wednesday. Craig Hallum lifted their target price on Bioventus from $12.00 to $17.00 and gave the company a “buy” rating in a research report on Friday, September 27th.

Bioventus Stock Performance

Shares of BVS opened at $11.24 on Friday. The stock has a 50-day simple moving average of $11.72 and a 200-day simple moving average of $8.33. The company has a debt-to-equity ratio of 1.82, a quick ratio of 0.96 and a current ratio of 1.33. The stock has a market capitalization of $910.10 million, a PE ratio of 36.08 and a beta of 0.88. Bioventus Inc. has a 1 year low of $3.36 and a 1 year high of $14.38.

Bioventus (NYSE:BVS) last posted its earnings results on Tuesday, November 5th. The company reported $0.06 earnings per share for the quarter, hitting the consensus estimate of $0.06. The firm had revenue of $138.96 million during the quarter, compared to analysts’ expectations of $132.57 million. Bioventus had a positive return on equity of 14.39% and a negative net margin of 7.82%. During the same quarter in the previous year, the business earned $0.05 earnings per share. On average, analysts predict that Bioventus Inc. will post 0.4 earnings per share for the current fiscal year.

Bioventus Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.